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The 26th annual meeting of the Society for Immunotherapy of Cancer took place in Bethesda on November 4 to 6,
2011 and was organized by Charles G. Drake (Johns Hopkins University) Dolores J. Schendel (Helmholtz Zentrum
Muenchen – German Research Center for Environmental Health Institute of Molecular Immunology), Jeffrey Schlom
(National Cancer Institute, National Institutes of Health), and Jedd D. Wolchok (Memorial Sloan-Kettering Cancer
Center). It was an event marked by a number of extraordinary circumstances: it attracted a record attendance of 805
participants from 24 different countries. The gathering came in the wake of great as well as very sad news for the
tumor immunology community. Good news included the approval of anti-CTLA-4 as a therapy for metastatic
melanoma in April and the announcement in early October of the Nobel Prize in Physiology and Medicine awarded
to pioneering studies in the field of immunology. Indeed, one part of the prize went to Dr. Bruce Beutler, Scripps
Research Institute, La Jolla, USA and Dr. Jules Hoffman, Institute for Molecular Cell Biology, Strasbourg, France, for
their discoveries in innate immunity and the other part to Dr. Ralph Steinman, The Rockfeller University, New York,
for his discovery of dendritic cells. Sad news was the losses of two giants in the field. Jürg Tschopp of the
University of Lausanne in March and Ralph Steinman, who passed away just three days before his Nobel Prize
announcement. The loss of these two charismatic scientific leaders was particularly sad for the Annual Meeting as
both J. Tschopp and R. Steinman were confirmed speakers at this meeting: the former to deliver the keynote
lecture and the latter as recipient of the Richard V. Smalley prize.Richard V. Smalley, MD memorial lectureship:
Ralph M. Steinman, MD and plenary session
biology and applications of dendritic cells
The first plenary session was a memorial to R. Steinman.
J. Banchereau, Roche, NJ, a close collaborator and
friend, made a vibrant recount of Dr. Steinman’s life and
scientific achievements. After reporting together with Z.
Cohn the new cell type and proposing the term “den-
dritic cell” in 1973, R. Steinman devoted the remaining
of his scientific career at The Rockefeller University to
study the properties of this cell. His efforts led him to
what we call today translational research, taking den-
dritic cells (DCs) into medicine and designing thera-
peutic vaccines. One of Steinman’s quotes evoked by Dr.
Banchereau was most fitting to the core business of the
Annual Meeting: “Immunology has the potential to iden-
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reproduction in any medium, provided the orprevention and therapies for infections, cancer, allergy,
autoimmunity and, transplantation”. Then, Dr. Bancher-
eau summarized their two approaches to DC vaccines:
ex vivo loading with the target antigens and in vivo tar-
geting of antigens to DC via the many receptors
expressed at their cell surface such as MMR, DEC-205,
DC-SIGN, Langerin, DCIR, LOX-1, ASGPR, CLEC-6,
Dectin-1, MARCO, CD1d, CD40. Interestingly, not all
receptors are equivalent and targeting DCs via distinct
lectins leads to distinct types of immune responses. In
his closing remarks, Banchereau called for increased col-
laboration between academia and pharmaceutical indus-
try with the aim of widening the base of target
identification and accelerating the discovery and transfer
of new therapeutic options to patient care.
R. Seeder of the Vaccine Research Center, NIAID, dis-
cussed important issues on the formulation and delivery
of proteins to DCs in order to optimize T cell immunity
and the use of “prime-boost immunization” with protein
and viral vaccines to improve T cell immunity. The use of
protein – TLR agonist conjugates would be particularly
advantageous to target receptors on DCs. He made the
case for TLR8 agonists, as TLR8 is expressed in threel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toid DC and the recently described cross-presenting,
CD141/BDCA-3, XCR1, TLR3 and TLR8 expressing DC,
human counterpart of the CD8α murine DC. Testing of
this idea with model antigens in mice showed that aggre-
gation of protein-imiquidazole conjugates enhanced up-
take by DC and that multiple DC subsets participated in
the initiation of specific T cell immunity. He also demon-
strated that specific CD8 T cells cross-primed by protein
conjugates were dramatically boosted by a recombinant
pox vector (NYVAC), suggesting its use as part of protein-
based therapeutic vaccine regimens.
E. Romano, University Hospital of Lausanne, Switzer-
land, discussed results generated while at J. W. Young’s
laboratory at Memorial Sloan-Kettering Cancer Center.
She found that human Langerhans cells can stimulate
robust CTL responses against tumor antigens, including
WT-1. While these cells do not make significant
amounts of IL-12, they express by far the highest
amounts of IL-15Rα which together with IL-15 support
the rapid generation of potent tumor reactive CTLs. Z.
N. Berneman, Antwerp University Hospital, Belgium,
presented promising results using DC vaccines for
leukemia in an adjuvant post-remission setting. The vac-
cine consists of autologous monocyte derived DCs that
are electroporated with mRNA encoding for WT-1, a
major transcription factor that is overexpressed in acute
myeloid leukemia and in a variety of solid tumors. It was
administered to AML patients during remission follow-
ing polychemotherapy. By measuring WT-1 mRNA in
serum, it was possible to detect the conversion of partial
remission into complete remission following vaccination
in 2 out of 3 patients, and the induction of molecular re-
mission following vaccination in 8 out of 17 AML
patients was detected. Several immunological effects cor-
related with clinical outcome including increased levels
of activated NK cells after vaccination and increased
WT1-specific tetramer +CD8 T cells post-vaccination
that correlated with long term clinical responses (CR
lasting over 3 years). Vaccination with genetically engi-
neered DCs may be an attractive strategy to prevent
AML relapse and warrants a phase II study in high risk
AML patients. S-R Woo, in the laboratory of T. F.
Gajewski, University of Chicago, reported the innate im-
mune sensing of tumors via the host STING pathway.
STING, stimulator of interferon genes, was identified in
2008 as a molecule essential to for effective innate im-
mune signaling processes. It is an endoplasmic reticulum
adaptor able to activate both NF-kB and IRF3 transcrip-
tion pathways to induce expression of IFN-α and IFN-β.
The question addressed was the nature of the DNA sen-
sor in DCs that drives the STING pathway in response
to tumor DNA. The results suggested that the intracellu-
lar DNA sensor IFI/p204, a PYHIN protein, is required.N. Bhardwaj closed the first session by discussing
modulation of DC function by the tumor microenviron-
ment. She presented a story of a complex network of
interactions in the processing and presentation of pep-
tides derived from the matrix metalloproteinase 2
(MMP2). MMP2 is recognized by both CD8 and CD4 T
cells in humans. Priming of inflammatory MMP2-
specific Th2 CD4 T cells required active MMP-2. Inter-
estingly, MMP2 acts as an endogenous Th2-conditioner
for other melanoma associated antigen-specific T cell
responses. MMP2 induces OX40L expression and inhi-
bits IL-12 production by DCs both of which are critical
for Th2 priming. MMP2 blocks IL-12 production via a
STAT1- and IFNβ/IFNAR-dependent mechanism. While
the conventional receptors for MMP2 on DCs were not
involved in imprinting DCs with the Th2 priming cap-
acity, it was found that its ability to directly degrade
IFNAR1 on DCs was the likely mechanism for imprint-
ing. Finally, her work also showed that upregulation of
OX40L by MMP2 occurs via its binding to TLR2 on the
surface of DCs.
Uncoupling negative regulation in the tumor
microenvironment
D. Pardoll, MD, PhD (John Hopkins University, School
of Medicine) co-chaired the session with H. Zarour, MD
(University of Pittsburgh). D. Pardoll discussed on the
therapeutic manipulation of the PD-1 checkpoint path-
way. In tumor-infiltrating lymphocytes (TILs) a high
proportion of CD8 T cells express PD-1, while neighbor-
ing tumor cells express the ligand PD-L1. This is linked
to both an adaptive resistance (i.e.: IFN-γ secretion by
infiltrating T cells inducing PD-L1 expression via STAT)
and an inflammatory phenotype (i.e.: increased propor-
tion of PD-L1 expression in primary melanomas com-
pared with metastatic lesions). PD-1 blockade (MDX
1106, Brystol-Myers Squibb) led to some tumor regres-
sion associated with increased TIL CD8 T cells and cor-
relation with positive PD-L1 expression by tumor cells.
S. Kerkar, MD (National Cancer Institute) reported on
IL-12 triggering of an inflammatory gene signature that
reverses dysfunctional antigen-presentation by myeloid
derived cells residing within tumors. In a B16 mouse
melanoma model, transferred IL-12-expressing CD8 T
cell showed enhanced anti-tumor activity through repro-
gramming of tumor-infiltrating myeloid-derived cells
leading to efficient cross-presentation of tumor-antigen.
J. Kline, MD (University of Chicago) showed how acute
myeloid leukemia (AML) promotes immune evasion via
the induction of antigen-specific T cell deletion. Com-
parison of AML murine models of solid and dissemi-
nated tumors showed an impaired antigen-specific T cell
response in the latter. This was not linked to suppres-
sion by Treg or MDSC, but to direct induction of T cell
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T cell dysfunction. H. Zarour, MD (University of Pitts-
burgh) discussed how targeting multiple inhibitory path-
ways may reverse melanoma-induced T cell dysfunction.
NY-ESO-1-specific CD8 T cells co-expressing PD-1 and
Tim-3 exhibited high degree of dysfunction, which could
be restored after blockade of both inhibitors. BTLA is
also upregulated in NY-ESO-1-specific T cells with half
of the cells co-expressing PD-1. This is in contrast to
the low expression of these inhibitory molecules on
virus-specific T cells. Studies ex-vivo showed that ex-
pression of PD-1 and Tim-3, but not BTLA, correlates
with levels of T cell function.
Characterization of Inflammatory infiltrates in
Human cancers
The session was co-chaired by W. H. Fridman, MD,
PhD (INSERM, France) and G. Coukos, MD, PhD (Uni-
versity of Pennsylvania Medical Center). G. Coukos
reported on chemokine regulation of T cell responses in
ovarian cancer. CCL28 is overexpressed in the hypoxic
ovarian tumor microenvironment. Suppressive Tregs are
recruited and accumulate at the tumor site through
CCR10 and CCL28. In mice, anti–CCR10-ZAP (immu-
notoxin) is an effective tool to deplete non specific Tregs,
without affecting CD8 T cells that instead express CCR3.
Interestingly, CCL28 over-expression also correlated with
enhanced VEGF expression; thus highlighting the syn-
ergy between immune tolerance and angiogenesis, as
repair mechanisms adopted by the tumor. M. Guidoboni,
MD (IRST Cancer Center Italy) discussed how DC vac-
cination may concurrently reduce Tregs and enhance
activated CTLs in tumor biopsies from immunorespon-
sive patients with advanced melanoma. Pre- and post-
vaccination TILs showed increased proportions of CD8
T cells without accumulation of Tregs. In progressing
patients, post-vaccination lesions had decreased specific
tumor-antigen expression, suggesting selection of tumor
cells expressing different antigens. W. H. Fridman dis-
cussed how tumor infiltration by various subsets of im-
mune cells can impact prognosis in analyses of large
cohorts of primary colorectal carcinoma. An immune
score based on tumor infiltration by T cells seems to be a
better prognostic factor in colorectal cancer compared
with the classical TNM staging system. A meta-analysis
showed a >90% concordance between presence of Th1
(CD8+ CD45RO+) cells and good prognosis; while, pres-
ence of Th17 cells seem to be associated with poor prog-
nosis. In lung cancer, surrounding high endothelial
venules that promoted B and T cells trafficking, lead to
formation of tertiary lymphoid structures (tumor-
induced bronchus-associated lymphoid tissues) that were
associated with favorable outcome. S. Adams, MD (New
York University Cancer Institute) showed how topicalTLR7 agonist, imiquimod, can induce immune–mediated
rejection of breast cancer skin metastases. Imiquimod
applied on skin metastases showed similar safety than in
genital warts and led to improved clinical outcome espe-
cially after subsequent therapy. A. Wesa, PhD (Celsense
Inc., Pittsburgh) reported on serial imaging of inflamma-
tion and therapeutic response with 19F MRI. In rat
models of rheumatoid arthritis, 19 F imaging visualized
phagocytic infiltration in the limb, which correlated with
disease status. V. Bronte, MD (Immunology Dpt., Uni-
versity of Verona, Italy) discussed how post-translational
chemokine modification can prevent intratumoral infil-
tration of antigen-specific T cells. Thus, in addition to
directly causing TIL unresponsiveness to stimuli, react-
ive nitrogen species generated in the tumors can induce
a permanent modification by nitration of CCL2 (N-
CCL2). N-CCL2 cannot attract TIL to the core of the
tumor, while recruitment of monocytes expressing
higher levels of CCR2, is retained. The use of a novel
nytrilation inhibitor (AT-38) in a murine model of pros-
tate cancer led to decreased N-CCL2 and stronger T cell
infiltration. In an adoptive therapy model, AT-38 chan-
ged the tumor microenvironment leading to better CTL
chemotaxis and tumor regression.
Prostate cancer as a learning model
This session was co-chaired by C. Drake, MD, PhD (John
Hopkins University) and J. Gulley, MD, PhD (National
Cancer Institute). C. Drake presented results on immune
checkpoint blockade in prostate and other cancers. A
single course of PD-1 blockade (MDX106) administered
two months after vaccination (GVAX) could lead to
tumor regression in a phase I trial in prostate cancer.
Immunohistological examination of tissue microarrays of
prostate tissue (from normal, benign hypertrophy, and
carcinoma samples) showed rather constant Treg or
Treg/CD8 ratio, while CD8/CD4 infiltration was higher
in normal versus malignant tissues. Fresh lymphocytes
from prostate gland needle biopsy (PIL) showed that 80%
of CD8 T cells expressed PD-1 and were functionally in-
active. PD-1 blockade was able to reverse proliferative
defect of PIL if Gleason score was = 6 but not if> 7. In a
murine model of glioblastoma, radiation combined with
PD-1 blockade resulted in higher tumor regression. D.
McNeel, MD, PhD (University of Wisconsin) discussed
how repeated DNA vaccination can elicits prostatic acid
phosphatase (PAP) antigen–specific T cell immune
responses in patients with castration-resistant prostate
cancer. Cellular immune responses, but not antibodies,
to this DNA vaccine were augmented after multiple
injections, though some patients never responded. An in-
crease in PAP-specific IFN-γ responses was associated
with a favorable change in PSA doubling time. K.-J.
Kallen, MD, PhD (CureVac, Germany) reported that
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vaccination technology induced strong T and B cell
responses in Phase I/II a trials in non-small cell lung
cancer and prostate carcinoma (PCA). CV9103 con-
sisted of a mixture of modified and active mRNA cod-
ing for multiple prostate tumor antigens able to induce
both humoral and cytolytic immune responses. After 5
vaccine doses, T cell responses were measured in 80%
of PCA patients with about 60% responding to more
than one antigen. T. De Gruijl, PhD (VU University
Medical Center, Netherlands) discussed about lymph-
oid and myeloid biomarkers for clinical outcome of
ipilimumab and prostate GVAX treatment and showed
that tumor-related CTLA-4 expression by CD4+ T
cells may be a dominant predictor of survival. Among
28 patients treated with GVAX and anti-CTLA-4, 5
showed partial regression and 12 stable disease. Occur-
rence of autoimmune adverse events was associated
with clinical response. Immunomonitoring showed that
increase in ICOS+ FoxP3+ Tregs and MDSCs was
associated with shorter survival, while high pretreat-
ment frequencies of CD4+CTLA4+ (but not Tregs)
correlated with longer survival. Cluster analysis corre-
lated low activation status with poor survival, and high
DC/low MDSC/low Treg pattern with good survival.
M. Provenzano, PhD (University of Zurich, Swizter-
land) presented a comprehensive characterization of
polyomavirus BK large tumor antigen (L-Tag) epitopes
that promote the expansion of effector T lymphocytes
in prostate cancer patients. Four potentially immuno-
genic BK L-Tag peptides were identified with a strong
ability to reactivate and maintain CTL in prostate
cancer patients. J. Gulley concluded the session by pre-
senting how combining vaccines with other therapeutics
may be a strategy to accelerate proof-of -concept stud-
ies. In contrast to chemotherapy, vaccination does not
improve time to progression (TTP), but increases over-
all survival. This is due to profound differences in the
mechanism of action of chemotherapy and immuno-
therapy. While chemotherapy rapidly, yet transiently,
kills sensitive tumor cells, immunotherapy, by boosting
endogenous immunity, can support cytotoxic and long-
lasting anti-tumor responses. Combination of targeted
radiation (Quadramet) or androgen deprivation (Fluta-
mide) with PSA-TRICOM vaccine showed longer TTP
than the single therapy. Similarly, combining a vaccine
(PANVAC) with Docetaxel in breast cancer patients
prolonged TTP to 274 days, as compared with 182 days
with Docetaxel alone.
Genetically engineered receptors and adoptive
cell therapies
Researchers have long tried to harness the power of the
immune system to fight cancer and overcome immunetolerance towards cancer cells; however, defining how to
best target functional T cells remains challenging. To
date, tumor immunotherapy with T cells, which can
recognize and destroy malignant cells, has been limited
by the ability to isolate and expand tumor-antigen spe-
cific T cells from the tumor (TIL). Gene transfer tech-
nologies provide the means to genetically modify T cells
to stably express antibody binding domains on their sur-
face that confer novel antigen specificities irrespective of
HLA type. C. June and his collaborators, Penn Univer-
sity, Philadelphia, have genetically modified T cells to ex-
press a chimeric antigen receptor (CAR) to yield CAR+
T cells expressing an anti-CD19 CAR including both
CD3-ζ and the 4-1BB costimulatory domain (CART19
cells) to target chronic lymphocytic leukemia (CLL), the
second most common type of leukemia in adults affect-
ing B cells. In a pilot clinical trial of CART19 cell adop-
tive transfer into three CLL patients, these cells
expanded> 1000-fold, persisted more that 6 months
in vivo and, retained anti-leukemic effects in a CD19-
specific fashion in all three patients examined. On aver-
age, each infused CAR+ T cell was estimated to kill at
least 1000 CLL cells. Some evidence for on-target tox-
icity included B cell aplasia and hypogammaglobuline-
mia. It was also found that those CART19 cells persisted
as both central and effector memory T cells, which likely
explains their longevity in vivo. The impressive results
achieved with this cellular therapy highlight the potential
of CAR-engineered T cells to usher in a new chapter in
cancer therapy; however, they generate some compelling
questions: why were CART19 cells not rejected? What is
the mechanism of long-term persistence, is it antigen-
dependent or independent? And finally, what is the
long-term safety of CAR-engineered T cells?
In line with recent developments to improve adoptive
T cell therapy of cancer, D. Schendel, Helmholtz Center,
Munich, and her collaborators described unanticipated
drawbacks in the application of allorestricted peptide-
specific T cells as sources of high-affinity TCR. As a
target antigen for adoptive T cell therapy, they selected
survivin, an apoptosis inhibitor protein that is overex-
pressed in many tumors. To obtain lymphocytes
expressing high affinity survivin-specific T cell recep-
tors, they isolated HLA-A2–allorestricted survivin-
specific T cells with high functional avidity. HLA-A2+
but not HLA-A2– survin-expressing lymphocytes under-
went extensive apoptosis due to HLA-A2–restricted
fratricide of survivin-expressing lymphocytes, which
naturally express ligands for specific TCR recognition.
These results raise a general question regarding the
development of cancer vaccines that target universal
antigens (i.e.: survivin and telomerase) expressed by a
variety of host cell types, including activated lympho-
cytes. Induction of high-avidity T cells might, indeed,
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elimination of neighboring T cells of other specificities.
Session: high throughput technologies for
immune monitoring
With the rapid advances in the development of potent
and specific immunomodulators as well as personalized
cellular therapies for control of cancer progression, the
design and validation of high throughput technologies
for immune monitoring represent a very hot topic
among immunologists and oncologists. These would
ideally allow the identification of biomarkers and base-
line patient characteristics associated with a response to
a given therapeutic approach and would ultimately
translate into the design of algorithms that guide clinical
decision.
At the SITC Annual meeting, a whole session was
dedicated to this topic and several outstanding speakers
lead the discussion. In the specific, S. Gnjatic, Ludwig
Institute for Cancer Research at Memorial Sloan Ketter-
ing Institute, New York, shared the great progress
made in the definition of humoral as well as cellular
biomarkers associated with response to treatment with
Ipilimumab, a monoclonal antibody against cytotoxic T
lymphocyte antigen 4 (CTLA-4), which has been shown
to improve survival in patients with advanced meta-
static melanoma. It also enhances both cellular and
humoral immunity to NY-ESO-1, a cancer/testis anti-
gen expressed in a subset of patients with melanoma.
NY-ESO-1-seropositive patients, either at baseline or
post-treatment, had a greater likelihood of experiencing
clinical benefit 24 wk after ipilimumab treatment than
NY-ESO-1-seronegative patients (P = 0.02, relative risk =
1.8, two-tailed Fisher test). Interestingly, NY-ESO-1-sero-
positive patients with associated CD8+ T cells experienced
more frequent clinical benefit (10 of 13; 77%) than those
with undetectable CD8+ T cell response, as well as a sig-
nificant survival advantage (P= 0.01; hazard ratio = 0.2,
time-dependent Cox model). Serological analysis of arrays
displaying the complete human proteome (seromics)
along with multiparametric T cell assays represent a new
era in cancer immunology and support their validation in
prospective studies.
Another yet-in-progress battle against cancer lies in
the identification of novel antigenic targets for immuno-
therapy. In this regard, P. Beckhove, German Cancer Re-
search Institute, Heidelberg, presented the results
generated with the ProteomeLab PF2D technology, in
which TAA analysis can be tailored to an individual pa-
tient. The investigators applied this method to human
tissue derived from head and neck as well as brain
tumors and identified MUC1 and EGFR as tumor-
associated antigens selectively recognized by T cells in
H&N cancer patients. In addition, they identified CD4+and CD8+ T cell responses against two novel antigens
transthyretin and calgranulin B/S100A9a in a patient
with a malignant brain tumor. This is emerging as a fast
and inexpensive method to identifying novel and poten-
tially immunogenic TAA irrespective of cell type and
HLA haplotype.
State of the art of animal models and veterinary
applications for cancer and immunology
T. Blankenstein, PhD, Max-Delbruck Center for Molecu-
lar Medicine, and J. D. Wolchok, MD, PhD, Memorial
Sloan-Kettering Cancer Center, co-chaired a session on
developing advances in animal models for cancer and
immunology. T. Blankenstein presented results of tumor
immune escape in a mouse model of sporadic cancer.
Conventional therapy results in initial tumor regression,
which leads to subsequent growth of resistant cell
clones. In this mouse model, tumors originating from
drug-resistant clones can be eradicated by adoptive
transfer of a specific CD8+ effector T cell. He demon-
strated that adoptively transferred T cells, as opposed to
chemotherapy, modulate tumor vasculature promoting
bystander elimination of tumor cells.
S. Spranger, Helmholtz Zentrum München, Germany,
discussed a mouse model that allows testing of human
dendritric cell-based immunotherapies and comparisons
in vivo of different vaccine strategies. Using an NOD/
scid/IL2Rγnull (NSG) mouse model, she observed that
vaccination using human-derived DCs matured with a
cocktail containing TLR7/8 agonists resulted in
enhanced immune responses. This model also allows
testing of different DC variants, as well as the immuno-
genicity of different immunizing antigens.
W. J. Murphy, PhD, University of California-Davis,
developed a xenogeneic model of orthotopic glioblast-
oma multiforme (GBM). He tested intracranial transfer
of human NK cells in combination with a human IL-15
gene therapy in NSG mice grafted with a GBM cell line.
Murphy observed an increased NK cell engraftment due
to the secretion of IL-15 and a significant tumor volume
reduction., This therapy did not protect mice from long-
term tumor relapse and death, however, it demonstrated
the feasibility of NK cell-based therapies for gliomas.
T. Merghoub, PhD, Memorial Sloan-Kettering Cancer
Center, presented transgenic mouse models of spon-
taneous melanoma created by expressing oncogenes
implicated in tumor development. TG-3 and Grm1
transgenic mouse strains develop melanoma at different
stages of tumor progression. Merghoub showed that
immunization with an optimized TYRP1 DNA vaccine,
while preventing Grm1 melanoma progression, resulted
inefficient in the aggressive TG-3 mouse model. He
demonstrated that resistance to treatment is due to
higher levels of regulatory T cells, and emphasized
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modulators.Presidential abstract session
The session brought together young investigators who
received the SITC presidential travel awards. All four
scientists were selected for 20-minute oral presentations.
This session was chaired by T. F. Gajewski, MD, PhD,
University of Chicago, the current SITC president.
J. Brody, MD, Stanford University Medical Center, pre-
sented the development of “immunotransplant” combin-
ing CpG vaccination, vaccine-primed T cell harvest,
myeloablation with stem cell rescue, and T-cell re-
infusion. In a preclinical model of lymphoma, immuno-
transplant induces a preferential Teff:Treg ratio and
amplifies anti-tumor T cells leading to the cure of sys-
temic lymphoma. In patients with mantle cell lymph-
oma, immunotransplant increases the proportion of
tumor-reactive T cells in 83% of patients and the upregu-
lation of activation markers.
L. Uccellini, PhD, Department of Transfusion Medi-
cine, NIH, presented an innovative study which analyzed
associations between melanoma immune responsiveness
and IRF5 polymorphism in TILs. His results support
that polymorphism of IRF5 appears to be a predictor of
the immune response to adoptive therapy with TILs in
metastatic melanoma.
L. V. Hurton, MD Anderson Cancer Center, The Uni-
versity of Texas-Houston, discussed the improvement of
transferred T-cell persistence in vivo. Hurton highlighted
the necessity to find alternatives to systemic administra-
tion of IL-2 to stimulate T-cell expansion because of its
high toxicity. She generated a membrane-bound IL-15
molecule (mbIL-15) to deliver localized IL-15 signaling
to T-cells. Human T cells were genetically modified to
express mbIL-15 in combination with CD19-specific
CAR. In mice bearing CD19+ malignancies, adoptively
transferred mbIL-15 +CAR+T cells demonstrated a bet-
ter in vivo T cell persistence and anti-tumor effect, with-
out the administration of exogenous cytokines.
Y. Zheng, PhD, Pathology, University of Chicago, fo-
cused on the functional anergy of TILs. She reported
that early growth response 2 transcription factor (Erg2)
is a central regulator of T cell anergy. Deletion of Egr2
prevents anergy in vitro and in vivo. This transcription
factor directly regulates most of the known anergy-
related genes like Crtam and Lag3. In the B16 melanoma
mouse model, she showed that 40–60% of TILs that
upregulated Crtam and Lag3 represented a subpopula-
tion of PD-1+ T cells with defective IL-2 production.
She concluded that cell surface markers to identify aner-
gic T cells might be useful to define therapeutic targets
for immunotherapy.Competing interests
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